Image via Motley Fool
Last updated
Legend Biotech: Capital Raising
First Beijing Investment Ltd acquired $43.78 million stake (2.3M shares) in Legend Biotech, a cancer cell therapy developer
Source: Motley Fool
The leadership read
Fresh capital is a hiring signal before it is anything else. For Legend Biotech, a raise in Biotech & Pharma funds leadership depth — scale, go-to-market and operational rigour — rather than any single appointment. Watch where Legend Biotech hires first across Asia; that is where the capital is really pointed.
Market context: Backdrop: a 104.6 (Hot) Talent Market Index (down 1.9 on the month) with Asia activity steady (-1pts).
Legend Biotech: 1 signal in the last 90 days — in line with the Biotech & Pharma median of 1 across 24 tracked companies; 0.1% of MitchelLake's Asia signal flow.
MitchelLake in this thematic
More signals across Biotech & Pharma
Restructuring · Asia
Samsung Biologics →Samsung Biologics unionized workers voted to leave the Samsung Group United Union and form an independent labor union, following months of work-to-rule campaigns and strikes over pay and working conditions.
Geographic Expansion · Asia
Thermo Fisher Scientific →Thermo Fisher Scientific's Manila Shared Services Centre is scaling rapidly from 100 to ~700 employees by 2026, positioning itself as a high-impact regional hub for Asia-Pacific operations with focus on digital transformation and strategic value creation beyond cost efficiency.
Geographic Expansion · Asia
Promomed Group →Promomed Group (Russian pharmaceutical company) is expanding into Vietnam's pharmaceutical market with strategic partnerships. Founder Petr Bely met with Vietnam's Minister of Health to discuss long-term cooperation, technology transfer, and manufacturing operations targeting innovative drugs, biosimilars, and monoclonal antibodies
Partnership · Asia
Bristol Myers Squibb →Bristol Myers Squibb partners with China's Hengrui Pharma on a $15.2 billion deal to advance more than a dozen early-stage drugs
Ma Activity · Asia
Gilead Sciences →Gilead Sciences agreed to acquire Ouro Medicines for up to $2.18 billion, gaining rights to antibody drug licensed from China's Keymed Biosciences
Capital Raising · Americas
Ratio Therapeutics →Ratio Therapeutics closed a Series C funding round of $70M for radiopharmaceutical trials, led by existing investors Duquesne Family Office and Bristol Myers Squibb, with new investor participation.
Intelligence powered by Autonodal ↗